Difference between revisions of "Inotuzumab ozogamicin (Besponsa)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.chemocare.com/chemotherapy/" to "https://chemocare.com/chemotherapy/") |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[B-cell acute lymphoblastic leukemia]] | *[[B-cell acute lymphoblastic leukemia]] | ||
| − | |||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Diffuse large B-cell lymphoma - historical|Diffuse large B-cell lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 34: | Line 36: | ||
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
| − | |||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| + | |||
| + | [[Category:Diffuse large B-cell lymphoma medications (historic)]] | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
[[Category:Pfizer product]] | [[Category:Pfizer product]] | ||
Revision as of 01:49, 28 April 2022
General information
Class/mechanism: Antibody targeting CD22, conjugated with a cytotoxic, antitumor antibiotic (calicheamicin). Inotuzumab demonstrates a dose-dependent cytotoxicity both in vitro and in vivo. [1][2][3][4]
Route: IV
Extravasation: No information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Diseases for which it is used
Diseases for which it was used
Patient drug information
- Inotuzumab ozogamicin (Besponsa) package insert[1]
- Inotuzumab ozogamicin (Besponsa) patient drug information (Chemocare)[5]
History of changes in FDA indication
- 8/17/2017: FDA approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). (Based on INO-VATE ALL)
Also known as
- Code name: CMC-544
- Brand name: Besponsa